

Press release from Emotra AB (publ)
Göteborg, February 13, 2015

Emotra's extraordinary shareholder meeting approved a share split

The shareholder meeting decided to follow the Board's recommendation and carry out a 2:1 share split. The purpose is to increase the number of shares in the Company in order to facilitate further trade in the share.

Preliminary schedule

February 20 Final day for trading in non-split shares
February 23 First day for trading in split shares
February 24 Record date for the split
February 26 Split shares entered in the Euroclear system

Number of shares before and after the split

Number of shares before the split: 2,595,780 shares
Number of shares after the split: 5,191,560 shares

For further information, please contact:

Claes Holmberg, CEO
Telephone: +46 708 25 45 47
E-mail: claes@emotra.se

Emotra AB is listed on AktieTorget, and the Company has developed a method – EDOR – of detecting depressed patients who are at risk of committing suicide. Altogether, more than 1,000 patients have been tested and followed up. EDOR has shown a reliability rate of up to 97%. In other words, Emotra's method can determine, with 97% certainty, if a person runs a significantly higher risk of suicide attempt, facilitating decisions about where special suicide prevention measures are needed. EDOR helps the right patients get the care they need.